HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Schneider, E. Articles by Fischer, P.-A. Search for Related Content PubMed PubMed Citation Articles by Schneider, E. Articles by Fischer, P.-A.

Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32–085

From the Department of Neurology, University Hospital, University of Frankfurt am Main, and Klinikum der Universitat, Schleusenweg 2–16, Frankfurt, West Germany.

8-alpha-amino-ergoline (CU 32-085) is a dopamine receptor agonist that should have fewer side effects than most other dopamine agonists. We studied the effect of this drug in 19 parkinsonian patients. In untreated or levodopa-treated patients, there was considerable improvement of akinesia, rigidity, and tremor; on-off symptoms also improved in the levodopa-treated patients. In patients pretreated with levodopahromocriptine, about half the dose of CU 32-085 was necessary to obtain the same therapeutic results, but there was no further improvement of on-off symptoms. Side effects were less pronounced than with bromocriptine; no circulatory disturbances and no psychotic episodes were observed.

Address correspondence and reprint requests to Dr. Schneider, Abteilung fur Neurologie, Klinikum der Universitat, Schleusenweg 2-16, 6000 Frankfurt am Main 71, West Germany.

Accepted for publication July 26, 1982